Who Supplies Sitagliptin to India from ISRAEL

Importing finished pharmaceutical formulations containing Sitagliptin into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. The importing company must obtain a valid Importer License from the Directorate General of Foreign Trade (DGFT). Each product must be registered with CDSCO, which involves submitting Form 40 or 41, depending on the product type. The registration process includes providing a No Objection Certificate (NOC) from the manufacturer, a Certificate of Pharmaceutical Product (CoPP), and stability data demonstrating compliance with ICH Zone IV guidelines. The timeline for import drug registration varies but typically ranges from 6 to 12 months. Sitagliptin formulations under HS Code 30049099 are subject to these requirements.

Imported Sitagliptin formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, must be provided to ensure product efficacy and safety. Upon arrival, customs drug inspectors conduct port inspections to verify documentation and sample products for testing. If a batch fails quality testing, it may be rejected, re-exported, or destroyed, depending on the severity of the non-compliance.

Between 2024 and 2026, CDSCO has implemented stricter regulations for importing finished pharmaceutical formulations, including Sitagliptin. The Production Linked Incentive (PLI) scheme has been expanded to encourage domestic manufacturing, potentially affecting the volume of imports. Bilateral agreements between India and Israel have facilitated smoother trade, but importers must stay updated on policy changes to ensure compliance.

India imports finished Sitagliptin formulations to meet the demand for patented and branded products not manufactured domestically. Specific dosage forms, such as combination tablets, may not be produced locally. Despite a robust domestic pharmaceutical industry, certain formulations are imported to fulfill market needs. The market size for Sitagliptin in India is substantial, with imports contributing significantly to the total consumption.

The import duty for Sitagliptin formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, a Secondary Higher Education Cess of 1%, and a Countervailing Duty (CVD) of 6%, totaling 17.10%. Additionally, the Integrated Goods and Services Tax (IGST) at 12% is applicable. There are no exemptions or concessional rates for imports from Israel.

India sources Sitagliptin formulations from Israel due to the availability of patented formulations and specialized dosage forms not produced domestically. Israeli manufacturers are known for high-quality standards and compliance with international regulations. While other countries like China, Germany, and the US also supply Sitagliptin formulations, Israel's competitive advantage lies in its innovation and quality assurance. Israel holds a significant share in India's Sitagliptin import market.

India imports Sitagliptin formulations from Israel due to the availability of patented and specialized dosage forms not produced domestically. Israeli manufacturers offer high-quality products that meet international standards, fulfilling specific market needs in India.

Compared to other sources like China, the EU, and the US, Israel offers competitive pricing, superior quality, and reliable supply chains. Israeli manufacturers' adherence to international regulatory standards and their focus on innovation provide a unique advantage in the Indian market.

Potential risks include reliance on a single supplier, currency fluctuations, regulatory changes, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, monitor currency trends, stay updated on regulatory developments, and establish contingency plans for logistics.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) to manage financial risk.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance.
5. 5Regulatory Compliance: Stay informed about changes in import regulations and ensure all documentation is current.

1. 1DGFT Importer Exporter Code (IEC): Obtain a valid IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Submit Form 40 or 41 for product registration with CDSCO.
3. 3Drug Import License: Secure a license from CDSCO for importing pharmaceutical products.
4. 4No Objection Certificate (NOC): Obtain an NOC from the manufacturer.
5. 5Customs Broker: Engage a licensed customs broker for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049099 to confirm classification and duty rates.

1. 1Certificate of Analysis (CoA): Confirming product quality and compliance.
2. 2Certificate of Pharmaceutical Product (CoPP): Indicating GMP compliance.
3. 3Good Manufacturing Practice (GMP) Certificate: Demonstrating adherence to international standards.
4. 4Drug Master File (DMF): Providing detailed product information.
5. 5Stability Data: Adhering to ICH Zone IV guidelines.
6. 6Free Sale Certificate: Indicating the product is freely sold in the country of origin.

7.